“Histone acetylation: Molecular memory aids on the chromatin”

Prof Johannes Gräff

Brain Mind Institute
School of Life Sciences
Ecole Polytechnique Fédérale de Lausanne
e-mail: johannes.graeff@epfl.ch

Invited by Jean-René Cardinaux
(Jean-Rene.Cardinaux@chuv.ch)

Salle Hirondelle, Hôpital Psychiatrique de Cery
Site de Cery, CH-1008 Prilly-Lausanne

Over the past decade, histone acetylation, a core epigenetic modification, has consistently been shown to favor learning and memory across a variety of species and memory tasks. In our own research, we could show that a lack of histone acetylation is causally implicated in cognitive decline associated with neurodegeneration. This effect was mediated, at least in part, by elevated levels of histone deacetylase 2 (HDAC2), but could be counteracted by shRNA-mediated knockdown of HDAC2, which also reinstated synaptic and structural plasticity in the neurodegenerating brain. Thus, elevated levels of HDAC2 seemingly induce an epigenetic blockade of cognitive functions in the neurodegenerating brain, but which is potentially reversible.

Furthermore, we found that a lack of histone acetylation memory aids is one of the causes for the failure of long-term traumatic memories to be updated using cognitive behavioral therapy-like methods in rodents. For long-term fear memories, histone acetylation was reduced in the hippocampus, the site for fear memory formation. This effect was mediated, at least in part, by reduced S-nitrosylation of HDAC2, which resulted in HDAC2 being persistently chromatin-bound. Nevertheless, by the use of HDAC2-targeting HDAC inhibitors, histone acetylation could be reinstalled, which primed neuroplasticity-related mechanism, such that even long-term traumatic memories could be permanently relearned.

Together, these results promote HDAC inhibitors as cognitive enhancers not only against cognitive decline associated with neurodegeneration, but also as adjuncts for behavioral therapies aimed at attenuating traumatic memories.

Selected Publications: